Dr. Nassir Rostambeigi, MD

Dr. Rostambeigi practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Rostambeigi's NPI, 1225349822, was assigned on June 29, 2010. Dr. Rostambeigi holds Missouri license 2019030117.

Dr. Rostambeigi's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Rostambeigi also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Rostambeigi's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Rostambeigi is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Rostambeigi to 2 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rostambeigi practices, 4 sites in all. Vendor and product names are available with a free account.

Vascular and interventional radiology is Dr. Rostambeigi's primary specialty in the NPI Registry, under taxonomy code 2085R0204X. Dr. Rostambeigi is licensed in Missouri.

CMS data shows 474 Medicare services from Dr. Rostambeigi across 11 procedure codes in 2024, for 199 Medicare patients. Medicare paid $34,693 for them.

CMS counts 199 Medicare patients who saw Dr. Rostambeigi in 2024. The largest group is 65 to 74, with 91 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rostambeigi's median patient age at 73, with 28% women.

In 2024, Dr. Rostambeigi wrote 63 Medicare Part D claims for 25 patients. 98% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $64 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Rostambeigi for performance year 2024, reported as part of a group. Dr. Rostambeigi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rostambeigi as offering telehealth.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 34 papers to Dr. Rostambeigi, published from 2011 to 2025. 2021 was the busiest year, with 4. The most frequent topics are Portasystemic Shunt, Transjugular Intrahepatic, Embolization, Therapeutic and Liver Transplantation. Dr. Rostambeigi has published most often in J Vasc Interv Radiol. Dr. Rostambeigi's most frequent co-authors are Jafar Golzarian, MD, Reza Talaie, MD and Yogish C. Kudva, MBBS.

CMS Open Payments shows 160 general payments to Dr. Rostambeigi from 17 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 37% of the total. Boston Scientific Corporation paid the most, $9,239.